Bayer's Actron OTC ketoprofen set to launch "within weeks".

BAYER'S ACTRON OTC KETOPROFEN LAUNCH COMING "WITHIN WEEKS," the company said, following FDA's Oct. 6 approval of the 12.5 mg strength of the NSAID for OTC analgesic indications. Calling Actron "extremely important" to the company and promising a "formidable launch," Bayer said it intends to support its new Rx-to-OTC switch with major promotional campaigns directed at consumers, physicians and pharmacists.

More from Archive

More from HBW Insight

International Self-Care Day: ‘Cyberchondria’ In The UK, Best Practices In The EU

 
• By 

On International Self-Care Day 2025 (July 24) PAGB releases its latest Self-Care Census which finds self-care confidence declining in the UK and AESGP launches a digital platform showcasing national-level self-care initiatives.

Euro Q2 Consumer Health Earnings Preview: Reckitt, Haleon, Bayer

 
• By 

Major Europe-based consumer health players Reckitt, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q2 2025 results over the coming weeks.